Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis
Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Department of Medical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey
Eur J Rheumatol ; : -
This article was viewed 395 times, downloaded 208 times
Key Words: Still’s disease, pulmonary aspergillosis, tumor necrosis factor-alpha inhibitors, infliximab
The use of anti-tumor necrosis factor alpha (anti-TNF-α) agents has increased during the past decade in rheumatology practice. Opportunistic infections have been reported with anti-TNF-α agents in clinical trials and post-marketing usage. Aspergillus infection is a rare opportunistic infection that is associated with immunosuppression, and there are reported cases of pulmonary aspergillosis in various rheumatic diseases treated with anti-TNF-α agents. Here, we present the first case of pulmonary aspergillosis associated with infliximab treatment in a patient with Still’s disease.